TY  - CONF

T1  - A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2–negative hormone receptor–positive breast cancer and bone metastases

JO  - Annals of Oncology

PY  - 2016/10/01

AU  - Rugo H

AU  - Petrenciuc O

AU  - Zhang A

AU  - Li R

AU  - Coleman RE

ED  - 

DO  - DOI: 10.1093/annonc/mdw365.89

PB  - Elsevier BV

VL  - 27

SP  - vi97

EP  - vi97

Y2  - 2025/10/10

ER  -